1. Evaluation of two (02) platforms for chemiluminescence-based detection of anti-rubella IgG antibodies in a sub-Saharan country, Côte d’Ivoire
- Author
-
Kady Mabity Bamba, Jea Luc Adjoumani, Aimé Cézaire Adiko, Roseline Affi-Aboli, André Inwoley, Rodrigue Denis Kouame, Bamory Dembele, and Tano Matthieu Kabran
- Subjects
Adult ,medicine.medical_specialty ,Sub saharan ,Adolescent ,Clinical Biochemistry ,Immunology ,Enzyme-Linked Immunosorbent Assay ,Cote d ivoire ,Prenatal care ,Antibodies, Viral ,01 natural sciences ,Rubella ,Serology ,law.invention ,Young Adult ,Pregnancy ,law ,medicine ,Humans ,Immunology and Allergy ,Chemiluminescence ,biology ,Obstetrics ,business.industry ,010401 analytical chemistry ,medicine.disease ,0104 chemical sciences ,Medical Laboratory Technology ,Cote d'Ivoire ,Immunoglobulin G ,Luminescent Measurements ,biology.protein ,Female ,Antibody ,business - Abstract
The diagnosis of rubella is mainly made in pregnant women and the newborn by specific IgG and/or IgM detection. In addition to HAI and ELISA techniques, new immunoanalytical methods have been developed. This study aimed to evaluate two chemiluminescence platforms, Architect i2000SR and Maglumi 800 for rubella biological diagnosis in Cote d'Ivoire. Blood samples were taken from 113 pregnant women aged 15 to 30 in prenatal care. Samples were analyzed for Rubella IgG detection at the NBTS laboratory on the evaluated platforms and the Cobas e601 used as a reference. The majority of women were in their second trimester of pregnancy. Among them, only 13.3% were vaccinated against rubella. The evaluated platforms showed good precision with coefficients of variation >10%. Regarding analytical performances, sensitivities were 97.53% and 96.29% whereas specificities were 100% and 96.88% for Architect I2000SR and Maglumi800, respectively. Both platforms showed good agreement with cobas e601 for antibody levels
- Published
- 2020